The Pretreatment Platelet Count is an Independent Predictor of Tumor Progression in Patients Undergoing Transcatheter Arterial Chemoembolization with Hepatitis B Virus-Related Hepatocellular Carcinoma

作者：Beili Wang, Feng Li, Luya Cheng, Yanxia Zhan, Boting Wu, Pu Chen, Junfei Shen, Wenhao Wu, Xiaolu Ma, Jie Zhu, Baishen Pan, Wei Guo, Yunfeng Cheng · 发表于：Future Oncology · 年份：2019 · DOI：10.2217/fon-2018-0591 · 被引用次数：21 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Inflammatory Biomarkers in Disease Prognosis、Organ Transplantation Techniques and Outcomes

AIM: To explore the prognostic value of the pretreatment platelet (PLT) count in patients undergoing transcatheter arterial chemoembolization (TACE) with hepatocellular carcinoma (HCC). MATERIALS & METHODS: We prospectively analyzed 317 hepatitis B virus-related HCC patients undergoing TACE. Time to progression (TTP) was selected to evaluate the clinical significance of PLT level in HCC patients. RESULTS: PLT was the only parameter showing statistical significance of all the clinical characteristics between two distinct tumor response groups. After ruling out cirrhosis as a potential major confounding factor, the conclusion was further established. Higher pretreatment PLT level, portal vessel invasion and higher stratification of α-fetoprotein level were independently associated with longer TTP. The prognostic score model combining the three risk factors revealed that higher risk scores might mean shorter TTP. CONCLUSION: The pretreatment PLT level is a potentially useful biomarker to predict the prognostic outcomes in HCC patients undergoing TACE and deserves to be further explored in subsequent works.